Register for email alerts and news feeds:
This journal | BMJ Group
rss
Drug and Therapeutics Bulletin 2004;42:93-96; doi:10.1136/dtb.2004.421293
Copyright © 2004 by the BMJ Publishing Group Ltd.

{blacktriangledown}Teriparatide for postmenopausal osteoporosis

Relevant BNF section: 6.6.1

{blacktriangledown}Teriparatide (Forsteo - Eli Lilly) is the first parathyroid hormone derivative to be licensed for the treatment of women with postmenopausal osteoporosis. It is described as a "bone-formation agent",1 in contrast to established treatments, such as bisphosphonates, raloxifene, calcitriol and calcitonin, which reduce bone resorption.2–4 Here we consider whether teriparatide offers any worthwhile advantages over these other options.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for email alerts

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Coming soon!

The DTB archive back to 1962, volume 1, issue 1 will soon be available.